Literature DB >> 26011933

Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes.

Witold Lasek, Michał Janyst, Rafał Wolny, Łukasz Zapała, Katarzyna Bocian, Nadzieja Drela.   

Abstract

Inosine pranobex (inosine dimepranol acedoben, isoprinosine) (Inos) is an immunomodulatory and antiviral drug used in some viral infections, especially in patients with weakened immunity. In the present study, effects of Inos on the production of cytokines attributable to Th1 (IL-2, IFN-g, and TNF-a) or Th2 cells (IL-4, IL-5, and IL-10) were tested in human peripheral blood lymphocyte cultures stimulated with phytohemagglutinin (PHA). Inos enhanced TNF-a secretion significantly (in short-term--24-hour, and prolonged term--72-hour cultures) and IFN-g (in 72-hour cultures). Surprisingly, production of IL-10 by PHA-stimulated lymphocytes was suppressed by Inos in a dose-dependent manner in both 24-hour and 72-hour cultures. These results shed some light on immunomodulatory properties of Inos and suggest applicability of this agent in patients with a depressed function of the immune system.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26011933     DOI: 10.1515/acph-2015-0015

Source DB:  PubMed          Journal:  Acta Pharm        ISSN: 1330-0075            Impact factor:   2.230


  9 in total

Review 1.  Exploration of the link between gut microbiota and purinergic signalling.

Authors:  MingJian Li; BoWen Liu; Rong Li; Ping Yang; Ping Leng; Yong Huang
Journal:  Purinergic Signal       Date:  2022-09-19       Impact factor: 3.950

Review 2.  A Review on Inosine Pranobex Immunotherapy for Cervical HPV-Positive Patients.

Authors:  Stefan Miladinov Kovachev
Journal:  Infect Drug Resist       Date:  2021-06-02       Impact factor: 4.003

3.  Inhibition of adenovirus multiplication by inosine pranobex and interferon α in vitro.

Authors:  Anna Majewska; Witold Lasek; Michał Janyst; Grażyna Młynarczyk
Journal:  Cent Eur J Immunol       Date:  2016-01-15       Impact factor: 2.085

4.  Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study.

Authors:  Jiří Beran; Eva Šalapová; Marian Špajdel
Journal:  BMC Infect Dis       Date:  2016-11-07       Impact factor: 3.090

Review 5.  Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases.

Authors:  Jiri Sliva; Chrysoula N Pantzartzi; Martin Votava
Journal:  Adv Ther       Date:  2019-06-05       Impact factor: 3.845

Review 6.  Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course.

Authors:  Jiří Beran; Marián Špajdel; Jiří Slíva
Journal:  Viruses       Date:  2021-11-09       Impact factor: 5.048

Review 7.  Mechanisms of Immunothrombosis by SARS-CoV-2.

Authors:  María Teresa Hernández-Huerta; Alma Dolores Pérez-Santiago; Laura Pérez-Campos Mayoral; Luis Manuel Sánchez Navarro; Francisco Javier Rodal Canales; Abraham Majluf-Cruz; Carlos Alberto Matias-Cervantes; Eduardo Pérez-Campos Mayoral; Carlos Romero Díaz; Gabriel Mayoral-Andrade; Margarito Martínez Cruz; Judith Luna Ángel; Eduardo Pérez-Campos
Journal:  Biomolecules       Date:  2021-10-20

8.  Influence of Inosine Pranobex on Cell Viability in Normal Fibroblasts and Liver Cancer Cells.

Authors:  Sylwia Tobólska; Sylwia Terpiłowska; Jerzy Jaroszewski; Andrzej Krzysztof Siwicki
Journal:  J Vet Res       Date:  2018-10-24       Impact factor: 1.744

9.  Genotoxicity and Mutagenicity of Inosine Pranobex.

Authors:  Sylwia Tobólska; Sylwia Terpiłowska; Jerzy Jaroszewski; Andrzej Krzysztof Siwicki
Journal:  J Vet Res       Date:  2018-10-24       Impact factor: 1.744

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.